Top Tech Companies (1,942)
Don't see your company?
Create a company profile
RxResults is a pharmacy benefits risk management company developing a suite of clinical tools to reduce cost.
Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells – both within the cell (mRNA), and, remarkably, to the cell - using what surrounds it. The trillions of non-human cells in the human ecosystem have evolved natural nanoparticles that precisely shuttle biomolecules into human cells, providing the missing pieces to fully unlock programmable medicines. Senda’s proprietary platform includes the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life – accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines. The unique properties of these medicines create new frontiers for mRNA therapeutics and vaccines for infectious, genetic, autoimmune, and metabolic diseases and oncology indications – with further potential to transform the gene editing and protein-based therapy landscapes as well. Based in Cambridge, MA, Senda was founded by Flagship Pioneering.
Metavention develops medical devices to help with interventional therapies for Type 2 diabetes.
Project Ronin is on a mission to transform cancer care by helping doctors and patients make better-informed decisions about treatment. Our cancer intelligence software provides all the information physicians need, in one place, to assess patient care options and take action. We use predictive technology to present doctors with different scenarios that can help them further optimize care. And, we bring the patient voice to the physician by allowing patients to report symptoms, side effects, and disease progression information via our mobile app, enabling real-time symptom management and true shared decision making with the care team. Project Ronin was founded by Dave Hodgson, one of the world’s leading architects of smart technology for doctors and patients; renowned cancer expert Dr. David Agus; serial health entrepreneur Rowan Chapman, PhD; and tech visionary Larry Ellison. We’re hiring!
Mapping the gut microbiome for better medicines
Vivex Biomedical is a biomedical company developing implant technology and stem cell therapies.
Transposagen Biopharmaceuticals provides animal models of human diseases for drug discovery and development.
Motitus is a consulting firm specializing in biotechnology, pharmaceuticals, healthcare, life sciences, and health tech, working with ambitious leaders. We bridge the gap between thinking and implementation with extraordinary impact. We deliver mission projects that transform your business into state-of-the-art for the industry.
Sumitovant is a global biopharma company with offices in New York and London. It is the parent company of five biopharmaceutical companies: Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and Spirovant Sciences. Our companies have a robust pipeline of innovative drug treatments targeting a broad range of diseases. • Sumitovant’s Digital Innovation approach integrates key skill sets, data sets and analytic tools to provide real answers to pharma’s most critical questions. With our tech-enabled approach to drug discovery, development and commercialization, we remove friction and accelerate every aspect of the process to bring promising new compounds to market. Sumitovant is wholly owned by Sumitomo Dainippon Pharma. Together, the Sumitomo Dainippon Pharma group of companies closely collaborate to expedite the discovery, development, and commercialization of truly innovative treatments. This collaboration harnesses the expertise of each organization with the goal of significantly improving patient outcomes and shareholder return.
Next generation traits company improving the yield, nutrition and sustainability of major global crops.
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.
Machine Learning for Drug Discovery. PostEra is building a modern biopharma, using machine learning to accelerate medicinal chemistry, to develop cures for diseases, faster. We've raised $26M from top investors, secured a $68M NIH partnership to prevent pandemics, and established a $260M partnership with Pfizer. We also launched and help lead the world's largest open-science initiative to find a COVID antiviral; COVID Moonshot.
We are Voyager Therapeutics, a pre-clinical stage biotech compelled by curiosity and powered by persistence. Voyagers are bold innovators who are energized in unlocking the full potential of AAV gene therapy employing our TRACER™ capsid discovery platform. Our resolve is to advance the field of AAV gene therapy, and through our innovative capsids, we are extending the reach and impact of our technology to help more patients in need. Recognizing that we can expand on the experience, innovation, and outcomes that propel our efforts by working together, we actively seek diverse views. If you’re someone who wants to make discoveries that change the landscape of medicine for patients, we want you on our team!
BioSTL builds regional capacity and fosters collaborative efforts to advance innovation,
Since our founding in 2003, NMT has made remarkable progress in bringing to market a comprehensive suite of innovative noninvasive
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Sciadonics is a biotech company that commercializes sciadonic acid and related fatty acids to combat their chronic inflammation epidemic.
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs. Learn more: www.AjiBio-Pharma.com
Heparinex is a biotechnology company.
Carterra is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra’s high throughput LSA™ instrument for monoclonal antibody (mAb) screening and characterization combines patented microfluidics technology with real-time High Throughput Surface Plasmon Resonance (HT-SPR) and industry leading Kinetic and Epitope analysis and visualization software, delivering up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing platforms. The LSA provides customers with screening and characterization throughput and functionality that matches the output from state-of-the-art antibody expression platforms. This enables all antibodies to be rapidly and comprehensively screened early in the discovery process so that unique epitopes and potential novel therapeutic candidates can be identified, while expanding and enhancing IP coverage. The Carterra LSA condenses months of work into a few days.
